[go: up one dir, main page]

AP2006003685A0 - Substituted quinoline compounds - Google Patents

Substituted quinoline compounds

Info

Publication number
AP2006003685A0
AP2006003685A0 AP2006003685A AP2006003685A AP2006003685A0 AP 2006003685 A0 AP2006003685 A0 AP 2006003685A0 AP 2006003685 A AP2006003685 A AP 2006003685A AP 2006003685 A AP2006003685 A AP 2006003685A AP 2006003685 A0 AP2006003685 A0 AP 2006003685A0
Authority
AP
ARIPO
Prior art keywords
substituted quinoline
quinoline compounds
compounds
substituted
quinoline
Prior art date
Application number
AP2006003685A
Other languages
English (en)
Inventor
Peter Bertinato
Michel Andre Couturier
Marcus Douglas Ewing
Ernest S Hamanaka
Ralph Pelton Robinson
Derek Lawrence Tickner
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AP2006003685A0 publication Critical patent/AP2006003685A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
AP2006003685A 2004-02-04 2005-01-24 Substituted quinoline compounds AP2006003685A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54167804P 2004-02-04 2004-02-04
US63376304P 2004-12-06 2004-12-06
PCT/IB2005/000167 WO2005080373A1 (en) 2004-02-04 2005-01-24 Substituted quinoline compounds

Publications (1)

Publication Number Publication Date
AP2006003685A0 true AP2006003685A0 (en) 2006-08-31

Family

ID=34890449

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2006003685A AP2006003685A0 (en) 2004-02-04 2005-01-24 Substituted quinoline compounds

Country Status (25)

Country Link
US (3) US7468378B2 (es)
EP (1) EP1716137A1 (es)
JP (1) JP2007520543A (es)
KR (1) KR100799802B1 (es)
AP (1) AP2006003685A0 (es)
AR (1) AR047529A1 (es)
AU (1) AU2005214159A1 (es)
BR (1) BRPI0507462A (es)
CA (1) CA2555133A1 (es)
CO (1) CO5700721A2 (es)
CR (1) CR8544A (es)
EA (1) EA010369B1 (es)
EC (1) ECSP066717A (es)
GE (1) GEP20084360B (es)
IL (2) IL176715A0 (es)
MA (1) MA28347A1 (es)
NL (1) NL1028192C2 (es)
NO (1) NO20063928L (es)
OA (1) OA13365A (es)
PA (1) PA8623001A1 (es)
PE (1) PE20050773A1 (es)
SV (1) SV2007002007A (es)
TW (2) TWI306454B (es)
UY (1) UY28734A1 (es)
WO (1) WO2005080373A1 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE551339T1 (de) 2003-11-05 2012-04-15 Sarcode Bioscience Inc Modulatoren der zellulären adhäsion
WO2005080373A1 (en) * 2004-02-04 2005-09-01 Pfizer Products Inc. Substituted quinoline compounds
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
US20070203139A1 (en) * 2004-04-14 2007-08-30 Astrazeneca Ab Aryl Glycinamide Derivatives And Their Use As Nk1 Antagonists And Serotonin Reuptake Inhibitors
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
GEP20104878B (en) 2005-04-19 2010-01-11 Surface Logix Inc Inhibitors of microsomal triglyceride transfer protein and apo-b secretion
EP2222631B1 (en) * 2006-10-23 2011-08-17 Pfizer Inc. Substituted phenylmethyl bicyclocarboxyamide compounds
EP2084127A1 (en) 2006-11-13 2009-08-05 Pfizer Products Inc. Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof
WO2008097471A1 (en) * 2007-02-02 2008-08-14 Shivvers Steve D High efficiency drier with multi stage heating and drying zones
WO2008100423A1 (en) * 2007-02-09 2008-08-21 Sirtris Pharmaceuticals, Inc. Gut microsomal triglyceride transport protein inhibitors
WO2009014674A1 (en) * 2007-07-23 2009-01-29 Sirtris Pharmaceuticals, Inc. Heterocyclylamides as gut microsomal triglyceride transport protein inhibitors
ES2748136T3 (es) 2007-10-15 2020-03-13 United Animal Health Inc Método para aumentar el rendimiento de las crías
ES2830024T3 (es) * 2007-10-19 2021-06-02 Novartis Ag Composiciones y métodos para el tratamiento del edema macular
WO2010018547A1 (en) * 2008-08-13 2010-02-18 Pfizer Inc. Aminoquinoline compounds
EP2723717A2 (en) 2011-06-24 2014-04-30 Amgen Inc. Trpm8 antagonists and their use in treatments
MX2013015058A (es) 2011-06-24 2014-01-20 Amgen Inc Antagonistas de melastatina 8 de potencial receptor transitorio y su uso en tratamientos.
BR112014002675A2 (pt) * 2011-08-04 2017-02-21 Array Biopharma Inc "quinazolina como inibidores de serina/treonina quinase, seus usos, e composição"
US8952009B2 (en) 2012-08-06 2015-02-10 Amgen Inc. Chroman derivatives as TRPM8 inhibitors
WO2015121877A2 (en) * 2014-02-17 2015-08-20 Hetero Research Foundation Polymorphs of lomitapide and its salts
PT3203840T (pt) 2014-10-06 2020-10-27 Vertex Pharma Moduladores do regulador da condutância transmembranar da fibrose quística
US10138206B2 (en) 2014-10-09 2018-11-27 Glenmark Pharmaceuticals Limited Amorphous form of lomitapide mesylate
US10738030B2 (en) 2016-03-31 2020-08-11 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
LT3519401T (lt) 2016-09-30 2021-11-25 Vertex Pharmaceuticals Incorporated Cistinės fibrozės transmembraninio laidumo reguliavimo moduliatorius, farmacinės kompozicijos, gydymo būdai ir moduliatoriaus gamybos būdas
MX2021013639A (es) 2016-12-09 2022-09-30 Vertex Pharma Forma cristalina del compuesto 1, un modulador del regulador de conductancia transmembrana de fibrosis quística, procesos para su preparación, composiciones farmacéuticas del compuesto 1, y su uso en el tratamiento de fibrosis quística.
CA3066084A1 (en) 2017-06-08 2018-12-13 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
EP3640242B1 (en) * 2017-06-16 2023-04-19 Hitgen Ltd. Rock-inhibiting compound and uses thereof
AU2018304168B2 (en) 2017-07-17 2023-05-04 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
CN111051280B (zh) 2017-08-02 2023-12-22 弗特克斯药品有限公司 制备吡咯烷化合物的方法
TWI719349B (zh) 2017-10-19 2021-02-21 美商維泰克斯製藥公司 Ｃｆｔｒ調節劑之結晶形式及組合物
MA51039A (fr) 2017-12-08 2020-10-14 Vertex Pharma Procédés pour préparer des modulateurs du régulateur de la conductance transmembranaire de la mucoviscidose
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
EP3774825A1 (en) 2018-04-13 2021-02-17 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2819039A1 (de) 1978-04-29 1979-11-08 Bayer Ag Leimungsmittel fuer papier
DK104382A (da) 1981-03-11 1982-09-12 Wellcome Found Fremgangsmaade til fremstilling af substituerede biphenylforbindelser
JP2527107B2 (ja) 1991-04-16 1996-08-21 日本新薬株式会社 固体分散体の製造方法
CA2091102C (en) 1992-03-06 2009-05-26 John R. Ii Wetterau Microsomal triglyceride transfer protein
US5595872A (en) 1992-03-06 1997-01-21 Bristol-Myers Squibb Company Nucleic acids encoding microsomal trigyceride transfer protein
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
CA2191352C (en) 1994-05-27 2001-01-30 Carlo Farina Quinoline derivatives as tachykinin nk3 receptor antagonists
DE19504832A1 (de) 1995-02-14 1996-08-22 Basf Ag Feste Wirkstoff-Zubereitungen
DE19519245C2 (de) * 1995-04-14 2003-04-30 Boehringer Ingelheim Kg Neue Arylglycinamidderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
EP0832069B1 (en) 1995-06-07 2003-03-05 Pfizer Inc. BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION
DK0832069T3 (da) 1995-06-07 2003-04-22 Pfizer Biphenyl-2-carboxylsyre-tetrahydroisoquinolin-6-ylamidderivater, deres fremstilling og deres anvendelse som inhibitorer af sekretion af mikrosomalt triglyceridoverførselsprotein og/eller apolipoprotein B (Apo B)
US5827875A (en) 1996-05-10 1998-10-27 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
KR20000065219A (ko) * 1996-05-20 2000-11-06 마르크 젠너 티엔에프 저해제 및 피디이-4 저해제로서의 퀴놀린 카르복사미드
IL121203A (en) 1996-07-01 2001-04-30 Lilly Co Eli 1, 2, 3, 4-tetrahydroisoquinidines, process for their preparation and pharmaceutical compositions containing the same for treating hyperglycemia and hyperlipidemia
KR100217618B1 (ko) * 1996-12-12 1999-09-01 정몽규 와셔액 분사위치 조절 장치
WO1998027979A1 (en) 1996-12-20 1998-07-02 Bristol-Myers Squibb Company Heterocyclic inhibitors of microsomal triglyceride transfer protein and method
US6066653A (en) 1997-01-17 2000-05-23 Bristol-Myers Squibb Co. Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs
US5968950A (en) 1997-06-23 1999-10-19 Pfizer Inc Apo B-secretion/MTP inhibitor hydrochloride salt
ATE364374T1 (de) 1997-08-11 2007-07-15 Pfizer Prod Inc Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit
AP1201A (en) 1997-09-17 2003-09-01 Smithkline Beecham Corp Method for the synthesis of quinoline derivatives.
JP2001526265A (ja) * 1997-12-22 2001-12-18 ファルマシア・アンド・アップジョン・カンパニー 抗ウイルス剤としての４−ヒドロキシキノリン−３−カルボキサミドおよびヒドラジド
CO5090829A1 (es) 1998-07-21 2001-10-30 Novartis Ag Compuestos organicos de la formula i, utiles como inhibido res de la proteina de transferencia de triglicerido microso mal y de la secrecion de la apolipoproteina b.
CA2325358C (en) 1999-11-10 2005-08-02 Pfizer Products Inc. 7-¬(4'-trifluoromethyl-biphenyl-2-carbonyl)amino|-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein b
CO5271688A1 (es) 1999-11-10 2003-04-30 Pfizer Prod Inc Uso de inhibidor de secrecion de apoliproteinas b y/o de proteina de transferencia de trigliceridos microsmales
US20020032238A1 (en) * 2000-07-08 2002-03-14 Henning Priepke Biphenylcarboxylic acid amides, the preparation thereof and the use thereof as medicaments
US6417367B1 (en) * 2000-08-11 2002-07-09 Pfizer Inc. Methods of making quinoline amides
MXPA03003002A (es) 2000-10-05 2004-12-06 Fujisawa Pharmaceutical Co Compuestos de benzamina como inhibidores de la secrecion de la apo b.
SI1404653T1 (sl) 2001-06-28 2008-12-31 Pfizer Prod Inc S triamidom substituirani indoli, benzofurani in benzotiofeni kot zaviralci mikrosomske prenašalnebeljakovine za trigliceride (MTP) in/ali izločanja apolipoproteina B (APO B)
SK2242004A3 (en) * 2001-10-25 2004-11-03 Takeda Chemical Industries Ltd Quinoline compound
US20030162758A1 (en) * 2001-12-07 2003-08-28 Schwartz Daniel M. Treatment for age-related macular degeneration (AMD)
US20030162788A1 (en) * 2002-01-10 2003-08-28 Boehringer Ingelheim Pharma Kg Combination of MTP inhibitors or apoB-secretion inhibitors with fibrates for use as pharmaceuticals
CN101838218A (zh) 2002-02-28 2010-09-22 日本烟草产业株式会社 酯化合物及其医药用途
WO2004056775A1 (en) * 2002-12-20 2004-07-08 Pfizer Products Inc. Microsomal triglyceride transfer protein inhibitors
CA2505604A1 (en) * 2002-12-20 2004-07-08 Pfizer Products Inc. Microsomal triglyceride transfer protein inhibitors
WO2005080373A1 (en) * 2004-02-04 2005-09-01 Pfizer Products Inc. Substituted quinoline compounds

Also Published As

Publication number Publication date
WO2005080373A1 (en) 2005-09-01
EA200601239A1 (ru) 2007-02-27
EP1716137A1 (en) 2006-11-02
UY28734A1 (es) 2005-09-30
US7468378B2 (en) 2008-12-23
US7393958B2 (en) 2008-07-01
OA13365A (en) 2007-04-13
SV2007002007A (es) 2007-03-20
MA28347A1 (fr) 2006-12-01
NL1028192A1 (nl) 2005-08-08
US20050234099A1 (en) 2005-10-20
TWI306454B (en) 2009-02-21
BRPI0507462A (pt) 2007-07-10
CR8544A (es) 2006-11-30
JP2007520543A (ja) 2007-07-26
AU2005214159A1 (en) 2005-09-01
US7368573B2 (en) 2008-05-06
US20060223851A1 (en) 2006-10-05
US20070093525A1 (en) 2007-04-26
KR100799802B1 (ko) 2008-01-31
CO5700721A2 (es) 2006-11-30
KR20060127123A (ko) 2006-12-11
ECSP066717A (es) 2006-10-31
AR047529A1 (es) 2006-01-25
IL176715A0 (en) 2006-10-31
TW200533354A (en) 2005-10-16
IL208963A0 (en) 2011-07-31
PA8623001A1 (es) 2006-03-24
CA2555133A1 (en) 2005-09-01
EA010369B1 (ru) 2008-08-29
GEP20084360B (en) 2008-04-29
NO20063928L (no) 2006-10-31
NL1028192C2 (nl) 2006-05-30
TW200906800A (en) 2009-02-16
PE20050773A1 (es) 2005-10-26

Similar Documents

Publication Publication Date Title
IL208963A0 (en) Substituted quinoline compounds
GB0405933D0 (en) Compounds
ZA200702228B (en) Carbostyril compound
IL182978A0 (en) Macrolones-amino substituted quinolones
GB0405193D0 (en) Compounds
GB0405272D0 (en) Compounds
GB0401269D0 (en) Compounds
GB0405267D0 (en) Compounds
GB0405101D0 (en) Compounds
ZA200605575B (en) Substituted quinoline compounds
GB0405280D0 (en) Compounds
GB0519969D0 (en) Quinoline compounds
GB0405893D0 (en) Compounds
GB0403593D0 (en) Compounds
GB0428061D0 (en) Novel Quinoline Compounds
GB0403595D0 (en) Compounds
GB0403594D0 (en) Compounds
GB0401653D0 (en) Compounds
GB0403267D0 (en) Compounds
GB0401657D0 (en) Compounds
GB0401656D0 (en) Compounds
GB0403990D0 (en) Compounds
GB0401654D0 (en) Compounds
GB0403998D0 (en) Compounds
GB0404081D0 (en) Compounds